Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The therapeutic value of adding a slow-release theophylline product (Theo-Dur) to the regular treatment program consisting of beta-stimulants and steroids was evaluated in 31 adult asthmatics. Theophylline in a dose of 300 mg or placebo was administered twice daily during two 14-day periods in a randomized double-blind cross-over study. PEF and asthma symptoms were recorded daily. In the morning, 12 h after tablet intake, spirometry was performed and the theophylline concentration determined. The addition of theophylline slightly, but statistically significantly, increased the daily PEF values and reduced dyspnoea, but not cough, sputum volumes and aerosol consumption. The patients showed preference for the combined treatment. Spirometry at the end of each period did not differ significantly between treatments. The mean theophylline concentration in the morning 12 h after tablet intake was 39 mumol/l (range 15-81 mumol/l). The results of the study suggest that the addition of a slow-release theophylline preparation to beta-stimulant therapy provides further relief of asthma symptoms without an unacceptable increase in the incidence of side-effects.
 ...
PMID:Combined theophylline/beta-agonists maintenance therapy in chronic asthma. 613 32

In 5 Viennese general practice offices we investigated patients by spirometry with the following indications: differential diagnosis of dyspnea; every 3rd smoker of more than 10 cigarettes a day (including asymptomatic ones); cough and nasal disorders of more than 4 weeks duration; indicative physical findings (cyanosis or auscultation). The sample control group was matched for age and gender and did not have any symptoms characteristic of the indication group. Nevertheless a spirometric test was also carried out in these patients. A total of 212 patients were examined in 4673 consultations on 202 workdays in the 5 offices. In the group of 109 patients 62 (56.9%) had dyspnea and/or positive signs on auscultation. Of these 62 patients 39 (62.9%) had 1 or more positive findings either from PEF or FEV 1 or both. There were significantly more referrals for X-rays in case of abnormal lung function. The control group of 103 obviously healthy persons in particular showed a significantly higher number of abnormal PEF values than expected (31 persons, 30.1%).
 ...
PMID:[Determination of forced expiratory volume (FEV 1) and maximal peak expiratory flow within the scope of routine diagnosis in general practice]. 802 27

In a multicenter group comparative study with 51 patients suffering from chronic obstructive lung diseases, efficacy and tolerance of physiotherapy with the VRP1 Desitin was investigated. In comparison with the control group (concomitant respiratory physiotherapy) a statistically significant increase in the lung function parameter VC, FEV1 and PEF was demonstrated in the VRP1 Desitin-group after 2 weeks of investigation. Auscultatory findings as well as the clinical symptoms cough, sputum and dyspnea were clearly improved. The patients observed an improvement in their condition and capability.
 ...
PMID:[Physical therapy with VRP1 in chronic obstructive respiratory tract diseases--results of a multicenter comparative study]. 830 24

The effect of 12 weeks therapy with nedocromil sodium given as MDI-aerosol, 8 mg/daily in a group of 20 atopic asthmatic patients was studied. The selected spirometric parameters (PEF, FEV1, FVC, FEF25-75%, Raw) and clinical symptoms of bronchial asthma (dyspnoea, cough, sputum) were assessed. Additionally the percentage reduction of bronchodilators usage was obtained. A significant improvement was observed in spirometric parameters. A statistically significant reduction in clinical symptoms of bronchial asthma and bronchodilators usage was noted.
 ...
PMID:[Analysis of selected spirometric parameters and results of therapy with nedocromil sodium in patients with asthma]. 840 44

In August 1986, gases from the Nyos volcanic lake killed 1,746 persons in northwestern Cameroun, but 1,500 others living in the affected area survived. Gas emanations contained carbon dioxide, sulfur dioxide, and hydrogen sulfide. The objective of this study was to evaluate the delayed respiratory consequences of the inhalation of such volcanic gases. Two groups of subjects living in the same area, exposed (Nyos group; n = 381) or not exposed (control group; n = 128) to Nyos gases, were evaluated with a short questionnaire and by measurement of peak expiratory flow (PEF, percent predicted) in March 1991. Eleven percent of the subjects smoked, more often men than women (23% vs 4%; p < 0.001). In the whole population (exposed and unexposed), smoking was associated with a 3.6-fold increase in the frequency of cough (p < 0.001) and with a 6-fold increase in the frequency of sputum production (p < 0.005), but not with a decrease in PEF. There was no difference in the frequency of dyspnea, cough, sputum production, and PEF between Nyos and control groups. We conclude that 55 months after the emanation of gases from Nyos volcanic lake, there was no difference in respiratory symptoms, and PEF between survivors who inhaled volcanic gases and control subjects, whereas smoking was associated with cough and sputum production.
 ...
PMID:Respiratory symptoms and peak expiratory flow in survivors of the Nyos disaster. 891 34

A 6 week randomised, multicentre parallel group study compared the efficacy and safety of fluticasone propionate (FP) dry powder inhaler 2 x 250 micrograms/d and flunisolide (FLUN) metered dose inhaler 2 x 500 micrograms/d. 169 patients with mild to moderate asthma (FEV1/VC > or = 60% predicted) participated. The final clinical judgement resulted from the change in FEV1 and symptom intensity (measured by the oxygen cost diagram = OCD). 79% of the patients in the FP group showed improvement or partial improvement, compared to 57% in the flunisolide group (p = 0.02). The results indicate a greater efficacy of FP concerning the intensity of dyspnea, cough and symptoms at night (p = 0.03). During the treatment period morning and evening PEF improved in both groups; in 81% of the FP patients and 71% of the FLUN patients. 50% of all patients had a FEV1 below 2.5 l/s. The greater efficacy of FP was especially found in patients with lower FEV1. In both treatment groups drug safety was judged good or excellent by most patients. The results of this 6 week study indicate a greater efficacy (FEV1 and symptoms) of FP 2 x 250 micrograms/d versus FLUN 2 x 500 micrograms/d. The study confirms that there is at least a 2:1 ratio in efficacy comparing FP with FLUN in asthma patients.
 ...
PMID:[Controlled clinical comparative evaluation of fluticasone powder inhalation versus flunisolide dose aerosol in patients with mild to moderate asthma]. 913 44

The study was designed to test for equivalence of asthma control between a new aerosol formulation of beclomethasone dipropionate (BDP) incorporating a chlorofluorocarbon-(CFC) free, hydrofluoroalkane propellant (HFA-134a) and the conventional beclomethasone aerosol formulated in CFC propellants. Sixty-eight asthmatic patients entered an eight-week, randomised, double-blind crossover study. All patients, previously stabilised on BDP, were randomised to receive the same dose of BDP from each of the study treatments. Statistically significant equivalence was demonstrated between HFA-BDP and CFC-BDP for asthma control parameters: FEV1, morning and evening PEF, sleep disturbance, wheeze and cough, morning breathlessness and bronchodilator use. Such equivalence was also demonstrated for safety parameters. To conclude, it has been demonstrated that HFA-BDP achieves a level of asthma control that is clinically and statistically equivalent to CFC-BDP in terms of efficacy and safety, at total daily doses ranging from 200 micrograms to 600 micrograms in asthma patients previously stabilised on inhaled CFC-BDP.
 ...
PMID:Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate. 915 65

The medical-environmental questionnaire, physical examination and pre-shift and post-shift spirometry have been performed in 48 furniture factory workers. The workers showed the work-related symptoms: cough, shortness of breath, chest pain, headache, general malaise, skin symptoms, eye symptoms, rhinitis. No relationship was found between the spirometry values and the frequency of the symptoms. The exposed workers showed a significant post-shift reduction of the FVC, FEV1, FEV1%VC and PEF (p < 0.001). The higher drops of the spirometric parameters occurred in younger workers. The presented data show that processing of wood may be associated with the work-related respiratory symptoms and diseases in exposed workers.
 ...
PMID:[The effect of wood dust on the respiratory system. Medical examination of furniture factory workers]. 919 Feb 35

We have evaluated the effect of formoterol in 28 patients (20 males and 8 females, mean age 25.4 years) affected by mild or moderate bronchial asthma due to Parietaria allergy. Inhaled formoterol was given at the dosage of 24 mg twice a day for 10 weeks during the pollen season. Patients had to record daily the peak respiratory flow, the severity and the number of asthmatic attacks and the severity of cough. Moreover they had to report the use of additional bronchodilators and the possible side effects. The treatment with formoterol obtained in increase of PEF values from 254 +/- 6.1 to 329 +/- 6.1 l/min in the morning and from 237 +/- 7.1 to 365 +/- 7.1 l/min in the evening. A significant improvement on the number of asthmatic attacks and on the cough was also obtained. No side effects have been reported. Our results show the safety and the efficacy of formoterol in the treatment of mild or moderate bronchial asthma.
 ...
PMID:[The effect of formoterol on light or moderate bronchial asthma due to allergy to Parietaria officinalis]. 926 10

Cetirizine, an antihistamine widely used in the treatment of allergic rhinoconjunctivitis, also has antiallergic activity. The present study aimed to evaluate cetirizine as a treatment for children with allergic cough due to pollen allergy. This was a parallel-group, double-blind, placebo-controlled, randomized study. Twenty children with pollinosis were enrolled: they were subdivided into two groups receiving a 1-month treatment during the pollen season. The following variables were monitored: 1) clinical symptoms and respiratory data (spirometry and PEF) evaluated at baseline and at the end of the study by allergists and by a daily diary card, and 2) pollen count. This study shows that cetirizine treatment reduces cough intensity (P < 0.05) and frequency (P < 0.01). In conclusion, cetirizine does clinically improve cough due to pollen allergy.
 ...
PMID:Cetirizine treatment of allergic cough in children with pollen allergy. 926 91


<< Previous 1 2 3 4 5 6 Next >>